UNSPSC 51112024: Idelalisib

A type of kinase Inhibitor

UNSPSC 51112024 Idelalisib, a Commodity code, covers procurement of this specific immunosuppressant pharmaceutical used to treat chronic lymphocytic leukemia and follicular lymphoma. State and local governments acquire idelalisib primarily through pharmacy benefit programs, Medicaid formularies, and employee health plans. The Texas Health and Human Services Commission's April 2026 Request for Information on direct-to-manufacturer prescription programs illustrates the current sourcing strategy — state health agencies are exploring pathways to procure specialty pharmaceuticals outside traditional pharmacy benefit manager and group purchasing organization channels, negotiating directly with manufacturers on net-pricing and outcomes-based models to manage costs for covered populations.

The recent activity under this code is concentrated in Texas, where HHS issued RFI No. HHS0017013 on April 3, 2026, to solicit vendor capabilities for implementing a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer relationships. The RFI seeks information from vendors with experience in direct contracting for self-insured employers and health plans, flexibility on negotiated net pricing without rebates, and capacity for value-based agreements. This is an exploratory phase — no award value, budget, timeline, or formal evaluation criteria are specified — and the state intends to use vendor responses to inform subsequent formal procurement strategy before issuing a full RFP.